Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections

Archives of Virology

Volumn 159, Issue 1, 2014, Pages 29-37

  Lin, Ming Tsung ^a   Chou, Yeh Pin ^a   Hu, Tsung Hui ^a   Yu, Hsien Chung ^b   Hsu, Yu Chun ^c   Tsai, Ming Chao ^a   Tseng, Po Lin ^a   Chang, Kuo Chin ^a   Yen, Yi Hao ^a   Chiu, King Wah ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VIRUS;

ADEFOVIR; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; TELBIVUDINE; THYMIDINE; VIRUS ANTIBODY;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY;

ADENINE; ADULT; AGED; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; THYMIDINE; TREATMENT OUTCOME;

EID: 84893720366     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-013-1786-4     Document Type: Article

References (32)

1. Hepatitis B Fact Sheet N°204 (2008) World Health Organization. http://www. who. int/mediacentre/factsheets/fs204/en/index. html.
2. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL (2006) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4: 936-962.
3. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C, Hepatitis B Virus Drug Resistance Working Group (2007) Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 46: 254-265.
4. Pais R, Benhamou Y (2010) Long-term therapy for chronic hepatitis B in HIV co-infected patients. Gastroenterol Clin Biol 34(Suppl 2): S136-S141.
5. Wang Q, Yang L, Mo L (2007) The evaluation and prediction of the effect of AIDS therapy. IEEE/ICME. 1591-1596.
6. Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS (2008) Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 13: 439-447.
7. Shaw T, Bartholomeusz A, Locarnini S (2006) HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 44: 593-606.
8. Zoulim F (2004) Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiv Res 64: 1-15.
9. Kukko C. HBV: Drugs in current clinical development. HCSP Version 4. 1, August 2008.
10. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y et al (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Eng J Med 357: 2576-2588.
11. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV, GLOBE Study Group (2009) 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136: 486-495.
12. Tsai MC, Chen CH, Lee CM, Chen YT, Chien YS, Hung CH, Wang JH, Lu SN, Yen YH, Changchien CS, Hu TH (2009) The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients. J Hepatol 50: 281-288.
13. Wang M, Long Q (2011) Modified robust variance estimator for generalized estimating equations with improved small-sample performance. Stat Med 30: 1278-1291.
14. Martus P, Stroux A, Jünemann AM, Korth M, Jonas JB, Horn FK, Ziegler A (2004) GEE approaches to marginal regression models for medical diagnostic tests. Stat Med 23: 1377-1398.
15. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125: 1714-1722.
16. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119: 172-180.
17. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN, Asia Hepatitis Lamivudine Study Group (2001) Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33: 1527-1532.
18. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouée-Durantel S, Villeneuve JP, Trépo C, Zoulim F (2005) Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41: 1391-1398.
19. Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V (2006) Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 13: 427-434.
20. Andreone P, Gramenzi A, Cursaro C, Biselli M, Cammà C, Trevisani F, Bernardi M (2004) High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 11: 439-442.
21. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Eng J Med 351: 1521-1531.
22. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS (2006) Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44: 283-290.
23. Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO, Byun KS, Lee CH (2006) Resistance to adefovir dipivoxil (ADV) in lamivudine resistant chronic hepatitis B patients treated with ADV. Gut 55: 1488-1495.
24. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO (2006) Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43: 1385-1391.
25. Chen CH, Wang JH, Lee CM, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS (2006) Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther 11: 771-778.
26. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M (2007) Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133: 1445-1451.
27. Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H (2011) Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. J Med Virol 83: 953-961.
28. Min AD, Dienstag JL (2007) Oral antivirals for chronic hepatitis B. Clin Liver Dis 11: 851-868.
29. Tenney DJ (2010) Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies. Antivir Ther 15: 529-535.
30. Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50: 661-662.
31. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, REVEAL-HBV Study Group (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73.
32. Doo E, Liang JT (2001) Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 120: 1000-1008.